Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Genabio Diagnostics has commercialized a broad portfolio of at-home and point-of-care diagnostic products. Their COVID‑19 Rapid Self-Test Kit received FDA Emergency Use Authorization and demonstrated high sensitivity in NIH RADx® Omicron variant studies. The company’s infectious disease, drug abuse, women’s health, metabolic monitoring, early cancer screening, and harm reduction tests are widely distributed in the US through major retailers/pharmacies as well as to hospitals/labs/government agencies. The company reports over $100 million in sales revenue since founding in late2019/2020.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Genabio Diagnostics.